$GH 0.49 Noisy

Notable posts

• @Venu_7_ bullish 182 eng

  IBD Top 15 - Week of July 20 $LQDA $DAVE $TVTX $ASTH $KNSA $GH $PATN $TGTX $HNGE $CRS $ENVA $OSCR $SEZL $KRYS $RSI You'd be surprised how many future leaders first show up on this list. Study them before everyone starts talking about them. https://t.co/pz90wm944Z

  view on X →
• @Venu_7_ bullish 117 eng

  Quite a few high-tight flags setting up here: $BB $ATEX $FROG $GH Strong prior runs, tight consolidation, and relative strength. Exactly the type of names worth keeping on the watchlist. https://t.co/Q5DXvC55sf

  view on X →
• @Venu_7_ neutral 140 eng

  IBD Top 15 – Week of July 13 $MU $ALAB $LQDA $CRDO $TVTX $DAVE $PTRN $AMD $CRS $TGTX $ASTH $GH $HNGE $OSCR $LRCX Study the leaders every single week. You don't need to own them all. You just need to understand why institutions do. https://t.co/emwzAhl7MC

  view on X →
• @Venu_7_ bullish 137 eng

  Biotech theme still looks so hot! $GH $ILMN $TVTX $XBI Most biotech names are in Stage 2 uptrends with massive relative strength & high tight flags, yet $XBI still hasn't broken its 2021 highs, which tells me how much room the sector may still have left. https://t.co/Nuvqe5wUsf

  view on X →
• @wallstengine bullish 27 eng

  GUARDANT HEALTH $GH Q2’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $335.0M (Est. $314M) 🟢; +44% YoY 🔹 Adj. EPS: -$0.42 (Est. -$0.41) 🔴 🔹 Screening Revenue: $52.9M; over 250% YoY 🔹 Adjusted EBITDA: -$55.9M (Est. -$50.3M) 🔴 Raises FY26 Guide: 🔹 Revenue: $1.34B-$1.36B (Est. $1.31B) 🟢; from $1.30B-$1.32B 🔹 Revenue Growth: 36% to 38%, from 32% to 34% 🔹 Oncology Revenue Growth: ~30%, from 28%-29% 🔹 Screening Revenue: $218M-$230M, from $186M-$198M 🔹 Non-GAAP Gross Margin: 64% to 65% 🔹 FCF Burn: $195M-$205M, raised from $185M-$195M Segment Net Revenue: 🔹 Oncology: $219.1M; +38% YoY 🔹 Biopharma & Data: $60.9M; +9% YoY 🔹 Screening: $52.9M; over 250% YoY Other Q2 Metrics: 🔹 Non-GAAP Gross Margin: 67%; +100 bps YoY 🔹 GAAP Gross Margin: 65%; flat YoY 🔹 Oncology Tests: ~104,000; +63% YoY 🔹 Free Cash Flow: -$69.5M Comments: 🔸 “Growth was fueled by strong oncology volume, with acceleration across every product. The landmark FDA approval of Guardant360 Liquid CDx further strengthens our portfolio and positions us to drive sustained growth in the years ahead.” 🔸 “The inclusion of the Shield blood test in the American Cancer Society’s screening guidelines, together with UnitedHealth Group’s broad coverage decision, represents powerful validation of Shield’s clinical utility and its potential to improve access to screening.”

  view on X →
• @Sam_Badawi mixed 47 eng

  Venu… Is a Rotation in Play? | The Solid Report Watch on YouTube @ 2:45 PM ET - Link ⤵️ https://t.co/fPsyJ0eBX6 Bouncing off Levels | $NVDA $AVGO $NBIS Buying Opportunity? | $HNGE $GH $LLY Pullback or Top? | $CRWD $RBRK $SNOW https://t.co/tCWtYdfG2W

  view on X →
• @WOLF_Financial neutral 10 eng

  Watching When Markets Rotate with Venu | The Solid Report Bouncing off Levels | $NVDA $AVGO $NBIS $HNGE $GH $LLY $CRWD $RBRK $SNOW https://t.co/KYb6y9rQq3

  view on X →